Last reviewed · How we verify

Other anti-psoriatic systemic treatments

Swiss Dermatology Network for Targeted Therapies · Phase 2 active Small molecule

Other anti-psoriatic systemic treatments is a Small molecule drug developed by Swiss Dermatology Network for Targeted Therapies. It is currently in Phase 2 development.

At a glance

Generic nameOther anti-psoriatic systemic treatments
SponsorSwiss Dermatology Network for Targeted Therapies
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Other anti-psoriatic systemic treatments

What is Other anti-psoriatic systemic treatments?

Other anti-psoriatic systemic treatments is a Small molecule drug developed by Swiss Dermatology Network for Targeted Therapies.

Who makes Other anti-psoriatic systemic treatments?

Other anti-psoriatic systemic treatments is developed by Swiss Dermatology Network for Targeted Therapies (see full Swiss Dermatology Network for Targeted Therapies pipeline at /company/swiss-dermatology-network-for-targeted-therapies).

What development phase is Other anti-psoriatic systemic treatments in?

Other anti-psoriatic systemic treatments is in Phase 2.

Related